Evaluation of Tissue Polypeptide Specific Antigen, CYFRA 21-1, and Carcinoembryonic Antigen in Nonsmall Cell Lung Carcinoma Does the Combined Use of Cytokeratin Markers Give Any Additional Information?

摘要: BACKGROUND Recently developed tissue polypeptide specific antigen (TPS) and CYFRA 21-1 assays determine the soluble cytokeratin 18 19 fragments, respectively, in serum. The authors compared value of TPS, 21-1, carcinoembryonic (CEA) for diagnosis, staging, prognosis, monitoring patients with nonsmall cell lung carcinoma (NSCLC). METHODS The study included 85 benign diseases 94 NSCLC. CEA serum levels were measured commercial kits. RESULTS The following demonstrated: 1) TPS levels, but not differed significantly between NSCLC operable disease (Stages I-IIIA) those inoperable IIIB-IV). 2) correlation coefficient increased progression from Stages I-IIIA (r = 0.41, P 0.04) to IIIB-IV 0.70, < 0.001). 3) Multivariate analysis identified as significant predictors survival, relative risks 2.57 (P 0.001) 2.05 0.01), respectively. For cases which both markers positive, risk was 6.4 0.0001) negative. 4) group disease, combined use allowed definition 3 sets different median survival times (14.3 months vs. 7.4 2.6 months). 5) percentages marker evaluations concordant results clinical assessments response therapy 75.0%, 72.2%, 61.1% CEA, respectively. CONCLUSIONS These findings suggest that, patients, are prognostic factors effective monitors therapy. these may provide additional information prognosis. Cancer 1998;82:1850-9. © 1998 American Society.